Tag: 300

GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.

MONACO, June 08, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe as the project’s exchange debut moves closer and Binance listing watch continues to build around the presale. The project has now crossed $1.48 million in total capital raised, Stage 17 is live at $0.01858, and holder growth has passed 9,300 while AlphaSwap demo traction and audit completion continue to support the project’s pre-listing profile.

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- GraniteShares has announced it will execute forward shares split for the several funds (the “Funds”). The total market value of the shares outstanding will not be affected as a result of these splits.

VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce its participation in Planet MicroCap Las Vegas 2026 Powered by MicroCapClub, taking place June 16-18, 2026, at the Bellagio Resort & Hotel in Las Vegas, Nevada.

Suominen Corporation’s stock exchange release on June 8, 2026, at 10:30 a.m. (EEST)

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido^®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: